Peringatan Keamanan

Animal studies to assess the effect of guselkumab on carcinogenesis, mutagenesis and impairment on fertility have not been conducted. When subcutaneously injected into guinea pigs, the doses of guselkumab up to 100mg/kg twice-weekly demonstrated no effects on fertility parameters FDA Label.

Guselkumab

DB11834

biotech approved investigational

Deskripsi

Guselkumab is a human immunoglobulin G1 lambda (IgG1?) monoclonal antibody that selectively blocks interleukin-23. IL-23 is an inflammatory cytokine that activates the CD4+ T-helper (Th17) cell pathway to mediate the inflammatory cascade that induces psoriatic plaque formation A20357. In clinical trials, guselkumab demonstrated improved skin clearance and symptomatic improvements in dermatological manifestations of psoriasis.

Developed by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.

Struktur Molekul 2D

Struktur tidak tersedia

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) Mean half-life of guselkumab is approximately 15 to 18 days in subjects with plaque psoriasis [FDA Label].
Volume Distribusi The apparent volume of distribution is 13.5 L [FDA Label].
Klirens (Clearance) Apparent clearance in subjects with plaque psoriasis is 0.516 L/day [FDA Label].

Absorpsi

Following a 100mg subcutaneous administration, the peak plasma concentration (Cmax) of guselkumab is 8.09 ± 3.68 mcg/mL which is reached after approximately 5.5 days FDA Label.

Metabolisme

Like other human IgG monoclonal antibodies, guselkumab is expected to be degraded into small peptides and amino acids via catabolic pathways FDA Label.

Rute Eliminasi

Like other human IgG monoclonal antibodies, guselkumab is expected to be both renally and fecally excreted as smaller peptide units.

Interaksi Obat

670 Data
Denosumab The risk or severity of adverse effects can be increased when Denosumab is combined with Guselkumab.
Etanercept The risk or severity of adverse effects can be increased when Etanercept is combined with Guselkumab.
Peginterferon alfa-2a The risk or severity of adverse effects can be increased when Peginterferon alfa-2a is combined with Guselkumab.
Interferon alfa-n1 The risk or severity of adverse effects can be increased when Interferon alfa-n1 is combined with Guselkumab.
Interferon alfa-n3 The risk or severity of adverse effects can be increased when Interferon alfa-n3 is combined with Guselkumab.
Peginterferon alfa-2b The risk or severity of adverse effects can be increased when Peginterferon alfa-2b is combined with Guselkumab.
Anakinra The risk or severity of adverse effects can be increased when Anakinra is combined with Guselkumab.
Interferon gamma-1b The risk or severity of adverse effects can be increased when Interferon gamma-1b is combined with Guselkumab.
Interferon alfa-2a The risk or severity of adverse effects can be increased when Interferon alfa-2a is combined with Guselkumab.
Aldesleukin The risk or severity of adverse effects can be increased when Aldesleukin is combined with Guselkumab.
Adalimumab The risk or severity of adverse effects can be increased when Adalimumab is combined with Guselkumab.
Gemtuzumab ozogamicin The risk or severity of adverse effects can be increased when Gemtuzumab ozogamicin is combined with Guselkumab.
Pegaspargase The risk or severity of adverse effects can be increased when Pegaspargase is combined with Guselkumab.
Infliximab The risk or severity of adverse effects can be increased when Infliximab is combined with Guselkumab.
Interferon beta-1b The risk or severity of adverse effects can be increased when Interferon beta-1b is combined with Guselkumab.
Interferon alfacon-1 The risk or severity of adverse effects can be increased when Interferon alfacon-1 is combined with Guselkumab.
Rituximab The risk or severity of adverse effects can be increased when Rituximab is combined with Guselkumab.
Basiliximab The risk or severity of adverse effects can be increased when Basiliximab is combined with Guselkumab.
Muromonab The risk or severity of adverse effects can be increased when Muromonab is combined with Guselkumab.
Ibritumomab tiuxetan The risk or severity of adverse effects can be increased when Ibritumomab tiuxetan is combined with Guselkumab.
Tositumomab The risk or severity of adverse effects can be increased when Tositumomab is combined with Guselkumab.
Alemtuzumab The risk or severity of adverse effects can be increased when Alemtuzumab is combined with Guselkumab.
Alefacept The risk or severity of adverse effects can be increased when Alefacept is combined with Guselkumab.
Efalizumab The risk or severity of adverse effects can be increased when Efalizumab is combined with Guselkumab.
Antithymocyte immunoglobulin (rabbit) The risk or severity of adverse effects can be increased when Antithymocyte immunoglobulin (rabbit) is combined with Guselkumab.
Interferon alfa-2b The risk or severity of adverse effects can be increased when Interferon alfa-2b is combined with Guselkumab.
Daclizumab The risk or severity of adverse effects can be increased when Daclizumab is combined with Guselkumab.
Phenylalanine The risk or severity of adverse effects can be increased when Phenylalanine is combined with Guselkumab.
Flunisolide The risk or severity of adverse effects can be increased when Flunisolide is combined with Guselkumab.
Bortezomib The risk or severity of adverse effects can be increased when Bortezomib is combined with Guselkumab.
Cladribine Guselkumab may increase the immunosuppressive activities of Cladribine.
Carmustine The risk or severity of adverse effects can be increased when Carmustine is combined with Guselkumab.
Amsacrine The risk or severity of adverse effects can be increased when Amsacrine is combined with Guselkumab.
Bleomycin The risk or severity of adverse effects can be increased when Bleomycin is combined with Guselkumab.
Chlorambucil The risk or severity of adverse effects can be increased when Chlorambucil is combined with Guselkumab.
Raltitrexed The risk or severity of adverse effects can be increased when Raltitrexed is combined with Guselkumab.
Mitomycin The risk or severity of adverse effects can be increased when Mitomycin is combined with Guselkumab.
Bexarotene The risk or severity of adverse effects can be increased when Bexarotene is combined with Guselkumab.
Vindesine The risk or severity of adverse effects can be increased when Vindesine is combined with Guselkumab.
Floxuridine The risk or severity of adverse effects can be increased when Floxuridine is combined with Guselkumab.
Indomethacin The risk or severity of adverse effects can be increased when Indomethacin is combined with Guselkumab.
Tioguanine The risk or severity of adverse effects can be increased when Tioguanine is combined with Guselkumab.
Vinorelbine The risk or severity of adverse effects can be increased when Vinorelbine is combined with Guselkumab.
Dexrazoxane The risk or severity of adverse effects can be increased when Dexrazoxane is combined with Guselkumab.
Beclomethasone dipropionate The risk or severity of adverse effects can be increased when Beclomethasone dipropionate is combined with Guselkumab.
Sorafenib The risk or severity of adverse effects can be increased when Sorafenib is combined with Guselkumab.
Streptozocin The risk or severity of adverse effects can be increased when Streptozocin is combined with Guselkumab.
Trifluridine The risk or severity of adverse effects can be increased when Trifluridine is combined with Guselkumab.
Gemcitabine The risk or severity of adverse effects can be increased when Gemcitabine is combined with Guselkumab.
Betamethasone The risk or severity of adverse effects can be increased when Betamethasone is combined with Guselkumab.
Teniposide The risk or severity of adverse effects can be increased when Teniposide is combined with Guselkumab.
Epirubicin The risk or severity of adverse effects can be increased when Epirubicin is combined with Guselkumab.
Chloramphenicol The risk or severity of adverse effects can be increased when Chloramphenicol is combined with Guselkumab.
Lenalidomide The risk or severity of adverse effects can be increased when Lenalidomide is combined with Guselkumab.
Altretamine The risk or severity of adverse effects can be increased when Altretamine is combined with Guselkumab.
Zidovudine The risk or severity of adverse effects can be increased when Zidovudine is combined with Guselkumab.
Cisplatin The risk or severity of adverse effects can be increased when Cisplatin is combined with Guselkumab.
Oxaliplatin The risk or severity of adverse effects can be increased when Oxaliplatin is combined with Guselkumab.
Cyclophosphamide The risk or severity of adverse effects can be increased when Cyclophosphamide is combined with Guselkumab.
Vincristine The risk or severity of adverse effects can be increased when Vincristine is combined with Guselkumab.
Fluorouracil The risk or severity of adverse effects can be increased when Fluorouracil is combined with Guselkumab.
Propylthiouracil The risk or severity of adverse effects can be increased when Propylthiouracil is combined with Guselkumab.
Pentostatin The risk or severity of adverse effects can be increased when Pentostatin is combined with Guselkumab.
Methotrexate The risk or severity of adverse effects can be increased when Methotrexate is combined with Guselkumab.
Carbamazepine The risk or severity of adverse effects can be increased when Carbamazepine is combined with Guselkumab.
Vinblastine The risk or severity of adverse effects can be increased when Vinblastine is combined with Guselkumab.
Fluticasone propionate The risk or severity of adverse effects can be increased when Fluticasone propionate is combined with Guselkumab.
Fluocinolone acetonide The risk or severity of adverse effects can be increased when Fluocinolone acetonide is combined with Guselkumab.
Linezolid The risk or severity of adverse effects can be increased when Linezolid is combined with Guselkumab.
Imatinib The risk or severity of adverse effects can be increased when Imatinib is combined with Guselkumab.
Triamcinolone The risk or severity of adverse effects can be increased when Triamcinolone is combined with Guselkumab.
Clofarabine The risk or severity of adverse effects can be increased when Clofarabine is combined with Guselkumab.
Prednisone The risk or severity of adverse effects can be increased when Prednisone is combined with Guselkumab.
Pemetrexed The risk or severity of adverse effects can be increased when Pemetrexed is combined with Guselkumab.
Fludrocortisone The risk or severity of adverse effects can be increased when Fludrocortisone is combined with Guselkumab.
Mycophenolate mofetil The risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Guselkumab.
Daunorubicin The risk or severity of adverse effects can be increased when Daunorubicin is combined with Guselkumab.
Irinotecan The risk or severity of adverse effects can be increased when Irinotecan is combined with Guselkumab.
Methimazole The risk or severity of adverse effects can be increased when Methimazole is combined with Guselkumab.
Etoposide The risk or severity of adverse effects can be increased when Etoposide is combined with Guselkumab.
Sulfasalazine The risk or severity of adverse effects can be increased when Sulfasalazine is combined with Guselkumab.
Dacarbazine The risk or severity of adverse effects can be increased when Dacarbazine is combined with Guselkumab.
Temozolomide The risk or severity of adverse effects can be increased when Temozolomide is combined with Guselkumab.
Penicillamine The risk or severity of adverse effects can be increased when Penicillamine is combined with Guselkumab.
Prednisolone The risk or severity of adverse effects can be increased when Prednisolone is combined with Guselkumab.
Sirolimus The risk or severity of adverse effects can be increased when Sirolimus is combined with Guselkumab.
Mechlorethamine The risk or severity of adverse effects can be increased when Mechlorethamine is combined with Guselkumab.
Azacitidine The risk or severity of adverse effects can be increased when Azacitidine is combined with Guselkumab.
Carboplatin The risk or severity of adverse effects can be increased when Carboplatin is combined with Guselkumab.
Methylprednisolone The risk or severity of adverse effects can be increased when Methylprednisolone is combined with Guselkumab.
Dactinomycin The risk or severity of adverse effects can be increased when Dactinomycin is combined with Guselkumab.
Cytarabine The risk or severity of adverse effects can be increased when Cytarabine is combined with Guselkumab.
Azathioprine The risk or severity of adverse effects can be increased when Azathioprine is combined with Guselkumab.
Doxorubicin The risk or severity of adverse effects can be increased when Doxorubicin is combined with Guselkumab.
Hydroxyurea The risk or severity of adverse effects can be increased when Hydroxyurea is combined with Guselkumab.
Busulfan The risk or severity of adverse effects can be increased when Busulfan is combined with Guselkumab.
Mycophenolic acid The risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Guselkumab.
Topotecan The risk or severity of adverse effects can be increased when Topotecan is combined with Guselkumab.
Mercaptopurine The risk or severity of adverse effects can be increased when Mercaptopurine is combined with Guselkumab.
Thalidomide The risk or severity of adverse effects can be increased when Thalidomide is combined with Guselkumab.

Target Protein

Interleukin-23 subunit alpha IL23A

Referensi & Sumber

Artikel (PubMed)
  • PMID: 24679469
    Sofen H, Smith S, Matheson RT, Leonardi CL, Calderon C, Brodmerkel C, Li K, Campbell K, Marciniak SJ Jr, Wasfi Y, Wang Y, Szapary P, Krueger JG: Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol. 2014 Apr;133(4):1032-40. doi: 10.1016/j.jaci.2014.01.025.
  • PMID: 24373779
    Levin AA, Gottlieb AB: Specific targeting of interleukin-23p19 as effective treatment for psoriasis. J Am Acad Dermatol. 2014 Mar;70(3):555-61. doi: 10.1016/j.jaad.2013.10.043. Epub 2013 Dec 24.
  • PMID: 26201310
    Gaspari AA, Tyring S: New and emerging biologic therapies for moderate-to-severe plaque psoriasis: mechanistic rationales and recent clinical data for IL-17 and IL-23 inhibitors. Dermatol Ther. 2015 Jul-Aug;28(4):179-93. doi: 10.1111/dth.12251.
  • PMID: 18177599
    Fitch E, Harper E, Skorcheva I, Kurtz SE, Blauvelt A: Pathophysiology of psoriasis: recent advances on IL-23 and Th17 cytokines. Curr Rheumatol Rep. 2007 Dec;9(6):461-7.

Contoh Produk & Brand

Produk: 9 • International brands: 0
Produk
  • Tremfya
    Injection • 100 mg/1mL • Subcutaneous • US • Approved
  • Tremfya
    Solution • 100 mg / 1 mL • Subcutaneous • Canada • Approved
  • Tremfya
    Injection • 200 mg/20mL • Intravenous • US • Approved
  • Tremfya
    Injection • 200 mg/2mL • Subcutaneous • US • Approved
  • Tremfya
    Injection, solution • 100 mg • Subcutaneous • EU • Approved
  • Tremfya
    Injection, solution • 100 mg • Subcutaneous • EU • Approved
  • Tremfya
    Injection, solution • 100 mg • Subcutaneous • EU • Approved
  • Tremfya
    Injection, solution • 100 mg • Subcutaneous • EU • Approved
Menampilkan 8 dari 9 produk.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul